A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension |
| |
| Authors: | Navreet Kaur Natt A Gupta G Singh T Singh |
| |
| Institution: | Department of Health and Family Welfare, CHC Manawala, SGRD Institute of Medical Sciences and Research, Amritsar, India;1Department of Pharmacology, Government Medical College, Patiala, Punjab, India;2Department of Ophthalmology, Government Medical College, Patiala, Punjab, India;3Department of Paediatrics, SGRD Institute of Medical Sciences and Research, Amritsar, India |
| |
| Abstract: | Aims:The aim was to compare efficacy and cost-effectiveness of bimatoprost 0.03% and brimonidine 0.2% in primary open-angle glaucoma (POAG)/ocular hypertension (OHT).Statistics:Independent samples t-test was used to compare the efficacy of both drugs.Results:IOP lowering with bimatoprost (8.9 ± 1.598 mm Hg) was significantly (P < 0.0001) higher than brimonidine (6.55 ± 1.26 mm Hg). The number of drops/ml were 33.43 ± 0.52 and 25.49 ± 0.26, respectively, for bimatoprost and brimonidine. Treatment with bimatoprost was costlier than brimonidine with daily costs/eye Rs. 4.02 ± 0.06 and 3.14 ± 0.03, yearly costs/eye Rs. 1467.46 ± 20.74 and 1147.75 ± 11.15, respectively. Bimatoprost was more cost-effective than brimonidine with the cost-effectiveness ratio (CER) respectively Rs. 13.10 ± 2.61/mm Hg and Rs. 13.96 ± 2.86/mm Hg. Incremental CER Rs. 10.43/mm Hg implies lower costs/mm Hg extra IOP lowering by bimatoprost than Rs. 13.96 for brimonidine.Conclusion:In spite of being costlier, bimatoprost is more efficacious and cost-effective than brimonidine. |
| |
| Keywords: | Cost-effectiveness glaucoma pharmacoeconomics |
|
|
